TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05134519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)
Description: Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
Study: NCT05206045

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care for patients with Sezary Syndrome
Study: NCT06222957

Intervention type: OTHER
Intervention: None (Observational study)
Description: Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.

Intervention type: OTHER
Intervention: None (Observational study)
Description: Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
Study: NCT04949087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenohumeral Injection
Description: Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral Injection
Description: Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
Study: NCT04535362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
Study: NCT04720170

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization
Description: Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
Study: NCT04411654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally as concomitant medication, followed by dose tapering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally as concomitant medication, followed by dose tapering.
Study: NCT06548295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Description: Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues
Study: NCT06497829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: geranylgeraniol
Description: GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
Study: NCT06498986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets
Description: Oral administration, 80mg daily for a cycle of 3 weeks.
Study: NCT04682327

Intervention type: OTHER
Intervention: Response to anti-PD-1/PD-L1
Description: Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.

Intervention type: OTHER
Intervention: Non-response to anti-PD-1/PD-L1
Description: Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
Study: NCT06049680

Intervention type: DRUG
Group type: OTHER
Intervention: SMOFlipid® (lipid injectable emulsion)
Description: SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Study: NCT06256627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
Description: Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
Description: Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count.
Study: NCT06071884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Percutaneous Nerve Field Stimulator
Description: The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
Study: NCT04449068

Intervention type: OTHER
Intervention: Neurological and neuropsychological Follow-up after deep brain stimulation
Description: Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
Study: NCT05688267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Mobility Training
Description: The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
Study: NCT05680129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecnoglutide high dosage
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecnoglutide low dosage
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study: NCT05619887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
Study: NCT06304844

Intervention type: DIAGNOSTIC_TEST
Intervention: transient elastography (Fibroscan)
Description: conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)

Intervention type: DIAGNOSTIC_TEST
Intervention: transient elastography (Fibroscan)
Description: conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)
Study: NCT05262595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 A
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT06003647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Educational module and video
Study: NCT05092464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Lactic Acid-enriched Cream
Description: The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
Study: NCT05001698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: intravenous infusion (IV)
Study: NCT05634941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ON-tDCS
Description: DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ON-tDCS
Description: For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
Study: NCT05569109

Intervention type: DEVICE
Intervention: doppler ultrasound
Description: doppler ultrasound on arteriovenous fistula in hemodialysis patients
Study: NCT05816161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique
Description: Exercises
Study: NCT06564831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLAM + SOC
Description: Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study: NCT06042985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The absorption effect between calcium citrate and calcium carbonate
Description: Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The absorption effect between calcium citrate and calcium carbonate
Description: Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
Study: NCT05816161

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Myofascial Release
Description: Exercises
Study: NCT06042985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The absorption effect between calcium citrate and calcium carbonate
Description: Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
Study: NCT05051098

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06140667

Intervention type: DEVICE
Group type: OTHER
Intervention: LarysealTM Pro
Description: The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu Aura Gain
Description: The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: \>100 kg) with maximum suction catheter size of 16 Fr.
Study: NCT05594563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFMO
Description: DFMO orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice a day
Study: NCT05204784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Description: After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Description: After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
Study: NCT05515679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRAIN App
Description: The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
Study: NCT06146738

Intervention type: BEHAVIORAL
Intervention: Palliative Care
Description: Best supportive care without surgical intervention

Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Tumor biopsy

Intervention type: PROCEDURE
Intervention: Tumor resection
Description: Maximal safe resection of the tumor
Study: NCT04802863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
Study: NCT04672746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief MI interaction via instant communication
Description: Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health information
Description: Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week.
Study: NCT06201013

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: urotherapy
Description: Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: urotherapy
Description: Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: urotherapy
Description: Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
Study: NCT05349318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
Study: NCT05262595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 B
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 D
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster aspart
Description: Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT05938088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I (mirogabalin group)
Description: Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Arm II (placebo group)
Description: It is performed in the same way as Arm l.
Study: NCT04736537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT
Description: CT imaging conceptually similar to time-lapse photography.